Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 4 de 4
Multiple Sclerosis Journal ; 27(2 SUPPL):631, 2021.
Article in English | EMBASE | ID: covidwho-1496009


Introduction: Ocrelizumab is an anti-CD20 humanized monoclonal antibody approved for the treatment of RRMS Objective: To describe clinical and analytical outcomes (lymphopenia, B-Cell and immunoglobulins evolution) with OCR and its correlation with infectious adverse events(AE). Methods: Data were retrospectively collected from 52 patients who received OCR in an MSUnit (between Nov/2016-May/2021). Incidence/grade of lymphopenia, B-cell percentage, IgM/IgG levels and infectious AE were collected. Results: 52 patients received OCR. Average age 39.5 years(SD8,7) Females:65.3%. Mean time since RRMSdiagnosis:11,1 years(1-27,3) Mean time of follow-up since OCR initiation:19months(SD15,1) Mean DMT previous OCR: 1,7DMT(SD1,1). 5 naïve. After OCR, annualized relapse rate(ARR) decreased from a median of 1 to 0. EDSS score decreased from 3,5(1.5-6.5) to 2,5(1.5-6.5). One patient had one relapse after 12 months receiving OCR. 19 patients showed 6-months CDI. 2 patients presented 6-months CDW. The rest remained stable. Cerebral MRI:Gd+ lesions diminished from 1,4 to 0. T2 lesion burden showed no changes. 11 patients had lymphopenia in at least one analytical determination after OCR(21.15%):5 grade II and 6 grade I lymphopenia. Average Bcell percentage diminished with OCR: baseline 14.3%(SD8.9);6-month 2.4%(SD2.6);12-month 1.5%(SD0.9);18- month 1,3%(0.9) Mean IgG levels diminished from 963,5(SD167,4) at baseline to 869,9(SD186,3) at 18-months. None below lower-limit of normality(LLN). Mean IgM levels diminished from 99,9(SD49,8) at baseline to 69,3(SD42,6) at 18-months.11 belowLLN. Infections occurred in 7 patients (3 urinary tract infection, 1 zoster, 3 covid-infection) All cases were mild and resolved with antibiotic/ symptomatic treatment. None required hospitalization. No correlation between infections and lymphocytes/immunoglobulin levels was found. Conclusion: In our sample, OCR treatment produced lymphopenia and persistent diminution of B-cell and immunoglobulins levels. We have not found correlation between these parameters and infectious AEs. This should be validated in further studies with longer samples and follow-up.

American Journal of Respiratory and Critical Care Medicine ; 203(9):1, 2021.
Article in English | Web of Science | ID: covidwho-1407145